Psychocorrective and cardiotropic therapy in young men with hypertension, overweight and androgen deficiency

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Men with testosterone deficiency with hypertension and overweight were treated. A reliable result was achieved within six months of treatment with an ACE inhibitor and an "alternative" classical hormone replacement therapy drug Leveton, which has a positive effect on biological age, regulates metabolism, reduces psycho-emotional stress, increases social adaptation, mental performance, improves mood, normalizes sleep. Early detection and timely treatment make it possible to avoid possible complications of cardiovascular diseases, allows to increase the effectiveness of combination therapy with ACE inhibitors and Leveton in men with androgen deficiency and overweight with hypertension at the level of blood pressure, remodeling of the heart, the state of the vascular bed, erectile dysfunction, psychological state.

Full Text

Restricted Access

About the authors

М. M. Khabibulina

Ural State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: m.xabibulina@mail.ru
ORCID iD: 0000-0002-3240-1357

Candidate of Medical Sciences

Russian Federation, Yekaterinburg

М. D. Shamilov

Ural State Medical University, Ministry of Health of Russia

Email: m.xabibulina@mail.ru
Russian Federation, Yekaterinburg

References

  1. Мамедов М.Н. Проблемы мужского здоровья в кардиологической практике. 2-е изд. М.: Кардиопрогресс, 2014 [Mamedov M.N. Men's health issues in cardiology practice. Ed. 2nd. M.: Kardioprogress, 2014 (in Russ.)].
  2. Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37 (29): 2315–81. doi: 10.1093/eurheartj/ehw106
  3. Vlachopoulos C., Ioakeimidis N., Terentes-Printzios D. et al. Plasma total testosterone and incident cardiovascular events in hypertensive patients. Am J Hypertens. 2013; 26: 373–81. doi: 10.1093/ajh/hps056
  4. Федорова Н.Н., Хабибулина М.М. Ремоделирование левых камер сердца у мужчин с артериальной гипертензией при нормальном и измененном гормональном фоне. Врач. 2015; 12: 25–6 [Fedorova N.N., Khabibulina M.M. Left cardiac remodeling in male hypertensive patients having a normal or altered hormonal profile. Vrach. 2015; 12: 25–6 (in Russ.)].
  5. Novo S., Iacona R., Bonomo V. et al. Erectile dysfunction is associated with low total serum testosterone levels and impaired flow-mediated vasodilation in intermediate risk men according to the Framingham risk score. Atherosclerosis. 2015; 238 (2): 415–59. doi: 10.1016/j.atherosclerosis.2014.12.007
  6. Федорова Н.Н., Хабибулина М.М. Структурные изменения миокарда левого желудочка у мужчин с артериальной гипертонией и андрогенодефицитом. Международный журнал экспериментального образования. 2015; 11 (5): 690–2 [Fedorova N.N., Khabibulina M.M. Structural changes in the left ventricle myocardia in men with arterial hypertension and androgenodeficiency. International Journal of Experiential Education. 2015; 11 (5): 690–2 (in Russ.)].
  7. Spitzer M., Basaria S., Travison T.G. et al. The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology. 2013; 1 (3): 475–82. doi: 10.1111/j.2047-2927.2013.00075.x
  8. Федорова Н.Н., Хабибулина М.М. Оценка показателей гормонального баланса у мужчин с артериальной гипертензией при различных типах ремоделирования левого желудочка. Казанский медицинский журнал. 2016; 97 (3): 323–7 [Khabibulina M.M., Fedorova N.N. Evaluation of normal balance indicators in men with arterial hypertension in various types of left ventricular remodeling. Kazan Medical Journal. 2016; 97 (3): 323–7 (in Russ.)]. doi: 10.17750/KMJ2016-323
  9. Lunenfeld B., Mskhalaya G., Zitzmann M. et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. AgingMale. 2015; 18 (1): 5–15. doi: 10.3109/13685538.2015.1004049
  10. Хабибулина М.М. Терапия при ремоделировании сердца у молодых мужчин с АГ, андрогенодефицитом и дислипидемией. Врач. 2019; 30 (3): 44–8 [Khabibulina M.M. Thearapy for cardiac remodeling in yong men with hypertension, androgen deficiency, and dyslipidemia. Vrach. 2019; 30 (3): 44–8 (in Russ.)]. doi: 10.29296/25877305-2019-03-09
  11. Карпов Ю.А. Ингибиторы АПФ: от снижения АД до профилактики осложнений и улучшения прогноза. Сердце. 2002; 4: 192–4 [Karpov Yu.A. ACE inhibitors: from lowering blood pressure to preventing complications and improving prognosis. Serdce. 2002; 4: 192–4 (in Russ.)].
  12. Постникова С.Л. иАПФ в кардиологической практике. РМЖ. 2004; 12 (7): 496–500 [Postnikova S.L. ACE inhibitors in cardiology practice. RMJ. 2004; 12 (7): 496–500 (in Russ.)].
  13. Дядык А.И., Багрий А.Э., Яровая Н.Ф. и др. Влияние ингибиторов ангиотензинпревращающего фермента на гипертрофию левого желудочка сердца у больных артериальными гипертониями. Терапевтический архив. 1995; 8: 65–7 [Dyadyk A.I., Bagrij A.E., Yarovaya N.F. et al. Effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with arterial hypertension. Terapevticheskij arxiv. 1995; 8: 65–7 (in Russ.)].
  14. Rosmond R., Wallerius S., Wanger P et al. A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. J Int Med. 2003; 254 (4): 386–90. doi: 10.1046/j.1365-2796.2003.01205.x
  15. Shores M.M., Matsumoto A.M., Sloan K.L. et al. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006; 166: 1660–5. doi: 10.1001/archinte.166.15.1660
  16. La Vignera S., Condorelli R., Vicari E. et al. Arterial erectile dysfunction: reliability of new markers of endothelial dysfunction. J Endocrinol Invest. 2011; 34 (10): 314–20. doi: 10.1007/BF03346728
  17. Мontorsi P., Montorsi F., Schulman C.C. Is erectile dysfuncttion the «tip of the iceberg» of a systemic vascular disorder? Eur Urol. 2003; 44: 352–4. doi: 10.1016/s0302-2838(03)00307-5
  18. Федорова Н.Н., Хабибулина М.М. Церебральная гемодинамика при артериальной гипертензии и андрогенодефиците. Врач. 2018; 29 (4): 26–32 [Khabibulina M.M., Fedorova N.N. Cerebral hemodynamics in hypertension and androgen deficiency. Vrach. 2018; 29 (4): 26–32. (in Russ.)]. doi: 10.29296/25877305-2018-04-04
  19. Blick C., Ritchie R.W., Sullivan M.E. Is Erectile Dysfunction an Example of Abnormal Endothelial Function? Curr Vasc Pharmacol. 2016; 14 (2): 163–7. doi: 10.2174/1570161114666151202205950
  20. Федорова Н.Н., Хабибулина М.М. Суточный профиль артериального давления у мужчин с гипертонической болезнью II стадии в зависимости от уровня тестостерона. Мат-лы IV Всеросс. конф. «Противоречия современной кардиологии: спорные и нерешенные вопросы». 2015; с. 40 [Fedorova N.N., Khabibulina M.M. Proceedings of the IV All-Russian Conference "Contradictions of modern cardiology: controversial and unresolved issues", 2015; р. 40 (in Russ.)].
  21. Gandaglia G., Briganti A., Jackson G. et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urology. 2014; 65: 968–78. doi: 10.1016/j.eururo.2013.08.023
  22. Viigimaa M., Vlachopoulos C., Doumas M. et al. Definition and Assessment of Erectile Dysfunction. Springer International Publishing, Switzerland, 2015; рр. 9–17.
  23. Хабибулина М.М. Способ диагностики развития эректильной дисфункции у молодых мужчин с артериальной гипертензией в зависимости от уровня тестостерона, показателей липидного спектра, ЭхоКГ-показателей. Патент на изобретение RU 2601405 C1 от 10.11.2016 [Khabibulina M.M. A method for diagnosing the development of erectile dysfunction in young men with arterial hypertension, depending on the level of testosterone, lipid spectrum, EchoCG parameters. Patent for invention RU 2601405 C1 of 10.11.2016 (in Russ.)].
  24. Bach L.E., Mortimer J.A., VandeWeerd C. et al. The association of physical and mental health with sexual activity in older adults in a retirement community. J Sex Med. 2013; 10 (11): 2671–8. doi: 10.1111/jsm.12308
  25. Dean J.D., McMahon C.G., Guay A.T. et al. The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. J Sex Med. 2015; 12 (8): 1660–86. doi: 10.1111/jsm.12952
  26. Clavijo R.I., Miner M.M., Rajfer J. Erectile Dysfunction and Essential Hypertension: The Same Aging-related Disorder? Rev Urol. 2014; 16: 167–71.27.
  27. Хабибулина М.М., Федорова Н.Н. Способ оптимизации лечения мужчин кардиотропной терапией и заместительной гормональной терапией при андрогенодефиците с артериальной гипертензией. Патент на изобретение RU 2632449 C1, 04.10.2017 [Khabibulina M.M., Fedorova N.N. A method for optimizing the treatment of men with cardiotropic therapy and hormone replacement therapy for androgen deficiency with arterial hypertension. Patent for invention RU 2632449 C1, 04.10.2017 (in Russ.)].
  28. Хабибулина М.М., Федорова Н.Н. Заместительная гормональная и кардиотропная терапия у молодых мужчин с АГ, избыточной массой тела и андрогенодефицитом. Врач. 2018; 29 (7): 78–83 [Khabibullina M.М., Fedorova N.N. Hormone replacement and cardiotropic thearapy in young men with hypertension, overweight, and androgen deficiency. Vrach. 2018; 29 (7): 78–83 (in Russ.)]. doi: 10.29296/25877305-2018-07-18
  29. Хабибулина М.М., Федорова Н.Н. Кардиотропная и заместительная гормональная терапия при сочетании АГ с андрогенодефицитом. Врач. 2016; 10: 65–9 [Khabibullina M.М., Fedorova N.N. Cardiotropic and hotmonereplacemen therapy for arterial hypertension concurrent with androgen deficiency. Vrach. 2016; 10: 65–9 (in Russ.)].
  30. Хабибулина М.М., Шамилов М.Д. Влияние глицина и лизиноприла на тревожность, социальное функционирование молодых мужчин с артериальной гипертензией и андрогенодефицитом. Врач. 2021; 32 (11): 83–6 [Khabibulina M., Shamilov M. The effects of glycine and lisinopril on anxiety, the social functioning of young males with hypertension and androgen deficiency. Vrach. 2021; 32 (11): 83–6 (in Russ.)]. doi: 10.29296/25877305-2021-11-17
  31. Хабибулина М.М., Шамилов М.Д. Влияние терапии глицином и лизиноприлом на качество жизни молодых мужчин с андрогенодефицитом и артериальной гипертензией. Врач. 2021; 32 (9): 38–41 [Khabibulina M., Shamilov M. The impact of glycine and lisinopril therapy on quality of life in young males with androgen deficiency and hypertension. Vrach. 2021; 32 (9): 38–41 (in Russ.)]. doi: 10.29296/25877305-2021-09-07
  32. Петрова Е.В., Елистратов Д.Г. Терапевтическая коррекция эректильной дисфункции и тревожно-депрессивных расстройств у пациентов с артериальной гипертензией. Врач. 2016; 4: 78–82 [Petrova E.V., Elistratov D.G. Therapeutic correction of erectile dysfunction and anxiety and depressive disorders in hypertensive patients. Vrach. 2016; 4: 78–82 (in Russ.)].
  33. Калинченко С.Ю., Тюзиков И.А., Ворслов Л.О. и др. Эректильная дисфункция: парадоксы и парадигмы современной патогенетической фармакотерапии. Сonsilium Мedicum. 2014; 16 (1): 78–82 [Kalinchenko S.Y., Tyuzikov I.A., Vorslov L.O. et al. Erectile dysfunction: paradoxes and paradigms of modern pathogenetic pharmacotherapy. Сonsilium Мedicum. 2014; 16 (1): 78–82 (in Russ.)].
  34. Петрова Е.В., Вакина Т.Н. Терапевтическая коррекция уровня дегидроэпиандростерона-сульфата и тестостерона при сексуальных дисфункциях. Врач. 2014; 1: 60–1 [Petrova E.V., Vakina T.N. Therapeutic correction level of dehydroepiandrosterone sulfate and testosterone in sexual dysfunctions. Vrach. 2014; 1: 60–1 (in Russ.)].
  35. Петрова Е.В., Вакина Т.Н., Бурмистрова Л.А. Сексуальные дисфункции при тревожно-депрессивных расстройствах. Лечащий врач. 2014; 5: 108–11 [Petrova E.V., Vakina T.N., Burmistrova L.A. Sexual dysfunction in anxiety and depressive disorders. Lechasсhi vrach. 2014; 5: 108–11 (in Russ.)].
  36. Petrova E., Shutov A. Therapeutic correction testosterone deficiency in hypertensive men with erectile dysfunction and depression. J Sex Med. 2016; 13 (5): 146. doi: 10.1016/j.jsxm.2016.03.172
  37. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67 (6): 361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x
  38. Finnell J.E., Wood S.K. Neuroinflammation at the interface of depression and cardiovascular disease: Evidence from rodent models of social stress. Neurobiol Stress. 2016; 4: 1–14. doi: 10.1016/j.ynstr.2016.04.001
  39. Atlantis E., Shi Z., Penninx B.J. et al. Chronic medical conditions mediate the association between depression and cardiovascular disease mortality. Soc Psychiatry Psychiatr Epidemiol. 2012; 47 (4): 615–25. doi: 10.1007/s00127-011-0365-9
  40. Berntson J., Stewart K.R., Vrany E. et al. Depressive symptoms and self-reported adherence to medical recommendations to prevent cardiovascular disease: NHANES 2005–2010. Soc Sci Med. 2015; 138: 74–81. doi: 10.1016/j.socscimed.2015.05.041

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Indicators of the psychological state of patients (questionnaire «Health, activity, mood») Note. * – p<0.05 significance of differences between the indicators before and after treatment.

Download (223KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies